{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:45Z","timestamp":1790089665355,"version":"4.0.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Effective therapeutic options remain limited for adults with relapsed or refractory (R\/R) warm autoimmune hemolytic anemia (wAIHA) and Evans syndrome (ES). We conducted a prospective, single-center, open-label clinical trial to evaluate the efficacy and safety of sirolimus. Adult patients with R\/R wAIHA or ES and hemoglobin levels &amp;lt;100 g\/L received oral sirolimus (1-3 mg\/day; target trough concentration, 4-15 ng\/mL) for \u22656 months. The coprimary end points were overall response rate (ORR) and complete response rate (CRR) at 6 months; secondary end points included 12-month efficacy, safety, and relapse rates. Seventy-eight consecutive patients were enrolled (median age, 52 years [interquartile range (IQR), 38-65]), including 63 (80.8%) with wAIHA and 15 (19.2%) with ES. With a median follow-up of 13.9 months (IQR, 12.7-17.0), sirolimus achieved a 6-month ORR of 80.7% (81.0% for wAIHA and 80.0% for ES) and CRR of 51.3% (52.4% for wAIHA and 46.7% for ES). Median times to overall and complete response were 2.4 months (IQR, 1.8-5.0) and 3.6 months (IQR, 2.3-7.0), respectively. Responses were sustained at 12 months (ORR, 78.2%; CRR, 50.0%). Treatment-emergent adverse events occurred in 28.2% of patients and were predominantly mild and reversible. Relapse and mortality rates were 12.7% and 2.8%, respectively. No baseline clinical characteristics were independently associated with response at 6 months. Sirolimus demonstrated clinically meaningful efficacy, durable responses, and a favorable safety profile, supporting its role as a steroid-sparing option for steroid-dependent patients and a potential treatment alternative for steroid-refractory R\/R wAIHA and ES. This trial was registered at www.clinicaltrials.gov as #NCT05925023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019844","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:14:48Z","timestamp":1781043288000},"page":"6198-6207","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Sirolimus for refractory\/relapsed warm autoimmune hemolytic anemia and Evans syndrome: a prospective study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5179-487X","authenticated-orcid":false,"given":"Qi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-8060","authenticated-orcid":false,"given":"Ziwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9216-746X","authenticated-orcid":false,"given":"Chen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-0694","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"15","key":"2026092210522772700_bib1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092210522772700_bib2","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"21","key":"2026092210522772700_bib3","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2015-01-588392","article-title":"The role of rituximab in adults with warm antibody autoimmune hemolytic anemia","volume":"125","author":"Dierickx","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026092210522772700_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2007.08.001","article-title":"Hemolytic anemia due to warm autoantibodies","volume":"22","author":"Packman","year":"2008","journal-title":"Blood Rev"},{"issue":"10","key":"2026092210522772700_bib5","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3324\/haematol.2014.114561","article-title":"Treatment of autoimmune hemolytic anemias","volume":"99","author":"Zanella","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2026092210522772700_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2026092210522772700_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA Study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"2026092210522772700_bib8","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.3390\/jcm9123859","article-title":"New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J Clin Med"},{"issue":"9","key":"2026092210522772700_bib9","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"2026092210522772700_bib10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood.2019003808","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026092210522772700_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27025","article-title":"Bortezomib and daratumumab in refractory autoimmune hemolytic anemia[J\/OL]","volume":"98","author":"McGlothlin","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2026092210522772700_bib12","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41375-023-01891-3","article-title":"Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias","volume":"37","author":"Nikitin","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"2026092210522772700_bib13","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(23)00034-0","article-title":"Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b\/2 study","volume":"10","author":"Liu","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026092210522772700_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ajh.27540","article-title":"Rituximab plus bortezomib for relapsed and refractory warm autoimmune hemolytic anemia: a prospective phase 2 trial","volume":"100","author":"Lin","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"2026092210522772700_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"issue":"5","key":"2026092210522772700_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjh.17655","article-title":"Daratumumab in rituximab-refractory autoimmune haemolytic anaemia","volume":"194","author":"Rieger","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"2026092210522772700_bib17","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","article-title":"Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease","volume":"8","author":"Jalink","year":"2024","journal-title":"Blood Adv"},{"key":"2026092210522772700_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of immune responses by mTOR","volume":"30","author":"Powell","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2026092210522772700_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T-cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2026092210522772700_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/08830185.2014.933957","article-title":"mTOR signaling in T-cell immunity and autoimmunity","volume":"34","author":"Liu","year":"2015","journal-title":"Int Rev Immunol"},{"issue":"4","key":"2026092210522772700_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ni.2005","article-title":"The kinase mTOR regulates the differentiation of helper T-cells through the selective activation of signaling by mTORC1 and mTORC2","volume":"12","author":"Delgoffe","year":"2011","journal-title":"Nat Immunol"},{"issue":"2","key":"2026092210522772700_bib22","doi-asserted-by":"crossref","first-page":"2282180","DOI":"10.1080\/07853890.2023.2282180","article-title":"Sirolimus is effective for primary refractory\/relapsed warm autoimmune haemolytic anaemia\/Evans syndrome: a retrospective single-center study","volume":"55","author":"Zhang","year":"2023","journal-title":"Ann Med"},{"key":"2026092210522772700_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.exphem.2020.08.001","article-title":"Sirolimus is effective for primary relapsed\/refractory autoimmune cytopenia: a multicenter study","volume":"89","author":"Li","year":"2020","journal-title":"Exp Hematol"},{"issue":"11","key":"2026092210522772700_bib24","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an International Working Group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2026092210522772700_bib25","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/S2352-3026(24)00144-3","article-title":"Diagnosis and management of Evans syndrome in adults: first consensus recommendations","volume":"11","author":"Fattizzo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026092210522772700_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2026092210522772700_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MBC.0000000000001303","article-title":"Clinical study reveals the efficacy of sirolimus in treating primary immune thrombocytopenia: findings from a single-center study","volume":"35","author":"Feng","year":"2024","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6 pt 2","key":"2026092210522772700_bib28","first-page":"562","article-title":"Clinical immunology and the physician","volume":"67","author":"Dacie","year":"1974","journal-title":"Proc R Soc Med"},{"issue":"4","key":"2026092210522772700_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12288-013-0290-z","article-title":"Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective","volume":"30","author":"Thabet","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"19","key":"2026092210522772700_bib30","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6198\/2588312\/blooda_adv-2026-019844-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6198\/2588312\/blooda_adv-2026-019844-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:38Z","timestamp":1790088758000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6198\/569042\/Sirolimus-for-refractory-relapsed-warm-autoimmune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019844","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,11]]}}}